Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Immunocore logo — Science to Transform Lives

Immunocore

Science to Transform Lives

Founded 2008 United Kingdom Abingdon, United Kingdom 603 employees IPO Total: $975.60M Biotechnology, Health Care +1

General Information

Company Name Immunocore
Founded Year 2008
Location United Kingdom Abingdon, United Kingdom +3
Employees 603
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage IPO
Social

Get notified when Immunocore moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Immunocore

Immunocore, founded in 2008 and headquartered in the United Kingdom, is a prominent player in the Biotechnology, Health Care, and Pharmaceutical industries. The company's slogan, "Science to Transform Lives," encapsulates its mission to develop groundbreaking T cell receptor (TCR) biological therapies. These therapies are formulated to address critical unmet needs in oncology, infectious diseases, and autoimmune diseases.

Recently, Immunocore secured a significant $300.00M through a Post Ipo Convertible investment on 01 January 2024. This robust financial backing underscores the market's confidence in their innovative capabilities and potential for monumental impact in its sectors. However, details on the investors involved in this round remain undisclosed.

Taxonomy: T Cell Receptor, Immunotherapy, Cancer Therapy, Oncology, Metastatic Melanoma, Infectious Diseases, Autoimmune Diseases, Bispecific Immunotherapies, TCR Technology Platform, Antibody Fragment Engineering, Clinical Trials, Drug Discovery, Biological Therapies, Unmet Patient Needs

Services & Products

Development of TCR therapies
Clinical trials management
Research in immunotherapy
Therapeutic pipeline development

Target Customers

Patients with cancer Patients with infectious diseases Patients with autoimmune diseases Healthcare professionals

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Convertible •••••• - 01 Jan 2024
Private Placement Vc •••••• 3
Investor Investor Investor
01 Jul 2022
Series C •••••• - 01 Feb 2021
Series B •••••• 8
Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Mar 2020
Series B •••••• 1
Investor
01 Sep 2017

View All 10 Funding Rounds

Immunocore Alternatives & Competitors

View All Alternatives
Immunocore vs
Intercept Pharmaceuticals
Intercept Pharmaceuticals United States

Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.

Post Ipo Debt
376 employees
Biotechnology, Health Care
Compare Immunocore vs Intercept Pharmaceuticals
Immunocore vs
Vandria SA
Vandria SA Switzerland

We develop first-in-class mitophagy inducers that rejuvenate cells to treat age-related and chronic...

Grant
14 employees
Manufacturing, Pharmaceutical
Compare Immunocore vs Vandria SA
Immunocore vs
CENSO BIOTECHNOLOGIES LTD
CENSO BIOTECHNOLOGIES LTD

A leading CRO with unparalleled expertise in intricate cell biology, focusing on human neurodegenera...

Series Unknown
1 employees
Biotechnology
Compare Immunocore vs CENSO BIOTECHNOLOGIES LTD
View all alternatives

FAQ About Immunocore

Science to Transform Lives
Immunocore was founded in 2008.
Immunocore is headquartered in Abingdon, United Kingdom.
Immunocore operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Immunocore has approximately 603 employees.
Immunocore has completed 10 funding rounds, raising a total of $975.60M. The latest funding stage is IPO.
Immunocore offers: Development of TCR therapies, Clinical trials management, Research in immunotherapy, Therapeutic pipeline development.
Top alternatives and competitors to Immunocore include Intercept Pharmaceuticals, Vandria SA, CENSO BIOTECHNOLOGIES LTD, Rubedo Life Sciences, Antlia Bioscience, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immunocore and Intercept Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Immunocore and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy